File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)

Article: Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing

TitleDiscovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing
Authors
Issue Date2020
Citation
Nature, 2020, v. 586 n. 7827, p. 113-119 How to Cite?
Abstract© 2020, The Author(s), under exclusive licence to Springer Nature Limited. The emergence of the novel SARS coronavirus 2 (SARS-CoV-2) in 2019 has triggered an ongoing global pandemic of severe pneumonia-like disease designated as coronavirus disease 2019 (COVID-19)1. The development of a vaccine is likely to require at least 12-18 months, and the typical timeline for approval of a novel antiviral therapeutic can exceed 10 years. Thus, repurposing of known drugs could significantly accelerate the deployment of novel therapies for COVID-19. Towards this end, we profiled a library of known drugs encompassing approximately 12,000 clinical-stage or FDA-approved small molecules. We report the identification of 100 molecules that inhibit viral replication, including 21 known drugs that exhibit dose response relationships. Of these, thirteen were found to harbor effective concentrations likely commensurate with achievable therapeutic doses in patients, including the PIKfyve kinase inhibitor apilimod2–4, and the cysteine protease inhibitors MDL-28170, Z LVG CHN2, VBY-825, and ONO 5334. Notably, MDL-28170, ONO 5334, and apilimod were found to antagonize viral replication in human iPSC-derived pneumocyte-like cells, and the PIKfyve inhibitor also demonstrated antiviral efficacy in a primary human lung explant model. Since most of the molecules identified in this study have already advanced into the clinic, the known pharmacological and human safety profiles of these compounds will enable accelerated preclinical and clinical evaluation of these drugs for the treatment of COVID-19.
Persistent Identifierhttp://hdl.handle.net/10722/286038
ISSN
2023 Impact Factor: 50.5
2023 SCImago Journal Rankings: 18.509
PubMed Central ID
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorRiva, Laura-
dc.contributor.authorYuan, Shuofeng-
dc.contributor.authorYin, Xin-
dc.contributor.authorMartin-Sancho, Laura-
dc.contributor.authorMatsunaga, Naoko-
dc.contributor.authorPache, Lars-
dc.contributor.authorBurgstaller-Muehlbacher, Sebastian-
dc.contributor.authorDe Jesus, Paul D.-
dc.contributor.authorTeriete, Peter-
dc.contributor.authorHull, Mitchell V.-
dc.contributor.authorChang, Max W.-
dc.contributor.authorChan, Jasper Fuk Woo-
dc.contributor.authorCao, Jianli-
dc.contributor.authorPoon, Vincent Kwok Man-
dc.contributor.authorHerbert, Kristina M.-
dc.contributor.authorCheng, Kuoyuan-
dc.contributor.authorNguyen, Tu Trinh H.-
dc.contributor.authorRubanov, Andrey-
dc.contributor.authorPu, Yuan-
dc.contributor.authorNguyen, Courtney-
dc.contributor.authorChoi, Angela-
dc.contributor.authorRathnasinghe, Raveen-
dc.contributor.authorSchotsaert, Michael-
dc.contributor.authorMiorin, Lisa-
dc.contributor.authorDejosez, Marion-
dc.contributor.authorZwaka, Thomas P.-
dc.contributor.authorSit, Ko Yung-
dc.contributor.authorMartinez-Sobrido, Luis-
dc.contributor.authorLiu, Wen Chun-
dc.contributor.authorWhite, Kris M.-
dc.contributor.authorChapman, Mackenzie E.-
dc.contributor.authorLendy, Emma K.-
dc.contributor.authorGlynne, Richard J.-
dc.contributor.authorAlbrecht, Randy-
dc.contributor.authorRuppin, Eytan-
dc.contributor.authorMesecar, Andrew D.-
dc.contributor.authorJohnson, Jeffrey R.-
dc.contributor.authorBenner, Christopher-
dc.contributor.authorSun, Ren-
dc.contributor.authorSchultz, Peter G.-
dc.contributor.authorSu, Andrew I.-
dc.contributor.authorGarcía-Sastre, Adolfo-
dc.contributor.authorChatterjee, Arnab K.-
dc.contributor.authorYuen, Kwok Yung-
dc.contributor.authorChanda, Sumit K.-
dc.date.accessioned2020-08-30T12:57:23Z-
dc.date.available2020-08-30T12:57:23Z-
dc.date.issued2020-
dc.identifier.citationNature, 2020, v. 586 n. 7827, p. 113-119-
dc.identifier.issn0028-0836-
dc.identifier.urihttp://hdl.handle.net/10722/286038-
dc.description.abstract© 2020, The Author(s), under exclusive licence to Springer Nature Limited. The emergence of the novel SARS coronavirus 2 (SARS-CoV-2) in 2019 has triggered an ongoing global pandemic of severe pneumonia-like disease designated as coronavirus disease 2019 (COVID-19)1. The development of a vaccine is likely to require at least 12-18 months, and the typical timeline for approval of a novel antiviral therapeutic can exceed 10 years. Thus, repurposing of known drugs could significantly accelerate the deployment of novel therapies for COVID-19. Towards this end, we profiled a library of known drugs encompassing approximately 12,000 clinical-stage or FDA-approved small molecules. We report the identification of 100 molecules that inhibit viral replication, including 21 known drugs that exhibit dose response relationships. Of these, thirteen were found to harbor effective concentrations likely commensurate with achievable therapeutic doses in patients, including the PIKfyve kinase inhibitor apilimod2–4, and the cysteine protease inhibitors MDL-28170, Z LVG CHN2, VBY-825, and ONO 5334. Notably, MDL-28170, ONO 5334, and apilimod were found to antagonize viral replication in human iPSC-derived pneumocyte-like cells, and the PIKfyve inhibitor also demonstrated antiviral efficacy in a primary human lung explant model. Since most of the molecules identified in this study have already advanced into the clinic, the known pharmacological and human safety profiles of these compounds will enable accelerated preclinical and clinical evaluation of these drugs for the treatment of COVID-19.-
dc.languageeng-
dc.relation.ispartofNature-
dc.titleDiscovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing-
dc.typeArticle-
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.1038/s41586-020-2577-1-
dc.identifier.pmid32707573-
dc.identifier.pmcidPMC7603405-
dc.identifier.scopuseid_2-s2.0-85088382800-
dc.identifier.volume586-
dc.identifier.issue7827-
dc.identifier.spage113-
dc.identifier.epage119-
dc.identifier.eissn1476-4687-
dc.identifier.isiWOS:000572353000001-
dc.identifier.issnl0028-0836-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats